NRGN and familial Alzheimer disease: Therefore, we aimed to characterize Ng in brain tissue and to quantify full-length Ng and Ng peptides in post-mortem brain tissue of patients with sAD, fAD, healthy controls as well as cognitively unaffected amyloid-positive (CU-AP) individuals, which have neuropathological changes beyond normal levels for their age.